Sanofi Finalizes Acquisition of Dynavax

Sanofi has successfully finalized its acquisition of Dynavax Technologies Corporation. The deal incorporates Dynavax's Hepatitis B vaccine, HEPLISAV-B, known for its two-dose regimen, and their pipeline including a shingles vaccine candidate. This acquisition marks a strategic move by Sanofi to enhance its stance in adult immunization, synergizing Dynavax's vaccine portfolio with Sanofi's global reach and commercial capabilities.

The tender offer for Dynavax shares concluded on February 9, 2026, with Sanofi promptly acquiring all shares. As a result, Dynavax becomes a wholly owned subsidiary, and its shares will no longer trade on NASDAQ. The acquisition is set to bolster Sanofi's vaccine development and broaden its market presence in key areas.